Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(III) acetate Manganese(III) acetate Manganese(III) acetate describes a family of coordination complexes with the approximate formula Mn(OCCH). All are brown solids, which are soluble in acetic acid and water. These compounds are used in organic synthesis as oxidizing agents. Compounds with the formula Mn(OCCH) have not been verified. Instead manganese(III) acetate adopts the structure reminiscent of those of basic chromium acetate and basic iron acetate. For this reason, manganese(III) acetate is sometimes referred to as basic manganese acetate. The formula is [MnO(OCCH)L]X where L is a ligand and X is an anion. The coordination polymer [MnO(OCCH)]OCCHHOCCH has been crystallized. It is usually